| Cat. No. |
Product Name |
Information |
| PC-60267 |
PHTPP
ERβ inhibitor
|
PHTPP is a potent, selective antagonist of estrogen ERβ receptor, exhibits 36-fold selective for ERβ. |
| PC-60063 |
Enclomiphene citrate
|
Enclomiphene citrate((E)-Clomifene, cis-Clomifene, RMI-16289, ICI-46476) is a nonsteroidal selective estrogen receptor modulator (SERM) that is under development for the treatment of male hypogonadism. |
| PC-45734 |
Elacestrant dihydrochloride
SERD
|
Elacestrant (RAD1901) dihydrochloride is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD). |
| PC-45733 |
Elacestrant
SERD
|
Elacestrant (RAD-1901) is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD). |
| PC-43271 |
AZD9496 maleate
|
A potent, selective estrogen receptor downregulator (SERD) with ER downregulation pIC50 of 9.68. |
| PC-43270 |
AZD9496
Estrogen receptor inhibitor
|
AZD9496 is a potent, selective estrogen receptor downregulator (SERD) with ER downregulation pIC50 of 9.68. |
| PC-42580 |
XCT790
ERRα inverse agonist
|
XCT790 (XCT-790) is a potent and selective ERRα inverse agonist with IC50 of 300-500 nM in transient transfection assays. |
| PC-46618 |
Clomiphene citrate
|
A non-steroidal, a widely used fertility agent that inhibits estrogen receptor in the hypothalamus. |
| PC-45541 |
Endoxifen hydrochloride
|
A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer.. |
| PC-45540 |
Endoxifen
SERM
|
Endoxifen is a metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer. |
| PC-45096 |
(Z)-4-Hydroxytamoxifen
|
A major metabolite of tamoxifen, a well-known Estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium. |
| PC-45768 |
SNG-1153
ERα36 inhibitor
|
SNG-1153 (SNG1153) is a derivate of icaritin that inhibits the growth of lung CSCs, targets abnormal ERα36 activity, inhibits cell growth and induces apoptosis of BCR-ABL+ leukemic cells. |
